Specialty Pharmacy Services in 2026: Where Compounding Fills the Gaps

Introduction: Specialty Pharmacy in 2026 Is More Than a Dispensing Channel

Specialty drugs are projected to exceed 60% of total U.S. pharmacy spending in 2026 while representing fewer than 5% of prescriptions written. When so much cost and clinical complexity are concentrated in so few prescriptions, the support infrastructure around those drugs matters as much as the drugs themselves.

This article moves past the familiar “specialty vs. compounding” debate. Instead, it maps the full modern service stack of specialty pharmacy: dispensing, adherence monitoring, prior authorization support, financial assistance coordination, clinical case management, and cold-chain delivery.

The core argument is straightforward. Compounding pharmacies such as Nationwide Compounding Rx® do not replace any of these six categories. They legally and clinically unblock specific failure points within them, including prior authorization (PA) denials, shortages, allergen conflicts, and discontinued formulations.

The 2026 backdrop makes this urgent:

• First-pass PA denial rates of 25% to 40% for specialty medications
• 227 active national drug shortages in Q2 2026
• A narrowing GLP-1 compounding pathway following the Fifth Circuit’s ruling
• New CMS prior authorization interoperability rules for drugs

What “Specialty Pharmacy Services” Actually Means in 2026

The National Association of Specialty Pharmacy (NASP) defines a specialty pharmacy as a state-licensed pharmacy that solely or largely serves patients with serious health conditions requiring complex therapies. By structural definition, it dispenses only FDA-approved, commercially manufactured drugs without altering them.

Definitions matter. SPAARx launched a national advocacy campaign after outlets including the New York Times, Wall Street Journal, and Washington Post used “specialty pharmacy” and “compounding pharmacy” interchangeably. This article respects that distinction throughout.

The scale of the specialty market is substantial, although estimates vary by methodology:

• U.S. specialty drug spend grew from $92.5B in 2023 to $129.2B in 2024.
• Trilliant Health projects the U.S. market could approach $965.5B by 2030.
• Other analyses place global specialty sales near $679B in 2024, trending toward roughly $1.6T by 2033.

Spending is also highly concentrated by therapeutic area. Oncology accounts for 47.1% of specialty drug revenue, followed by bleeding and blood disorders (13.6%) and inflammatory conditions (8.1%). Cell and gene therapies are reshaping the field, with 46 FDA-approved therapies as of October 2025 and more than 500 in the pipeline.

Given this complexity, “specialty pharmacy services” is best understood as six distinct service categories rather than as simple dispensing.

The Six Core Service Categories of Specialty Pharmacy

Specialty pharmacy accreditation formally evaluates these operational modules through URAC (now on version 6.0), ACHC, CPPA, and The Joint Commission. URAC is preferred by roughly 66% of commercial payers, and more than 1,900 dispensing locations hold specialty accreditation nationwide. Each category below has a real structural strength and an inherent limitation.

Dispensing of FDA-Approved Specialty Medications

Specialty pharmacies dispense commercially manufactured, FDA-approved drugs exactly as produced, with no changes to formulation, strength, or ingredients. The market is highly concentrated: in 2024, the three largest specialty pharmacies, all owned by vertically integrated PBM or health-system organizations, accounted for two-thirds of specialty prescription revenue.

The limitation: if a patient cannot tolerate the commercial formulation because of an allergen, dosage form, or strength, or if the drug is on shortage, dispensing structurally cannot adapt.

Adherence Monitoring

Specialty pharmacies track refill timing, conduct side-effect check-ins, and make outreach calls to keep patients on complex regimens. Yet nearly 30% of specialty pharmacy patients discontinue treatment because of affordability and insurance restrictions, underscoring that monitoring alone cannot solve dropout driven by cost or access.

The limitation: adherence tools can flag a problem, such as a patient stopping because of pill burden or taste aversion, but they are not designed to fix the formulation issue behind it.

Prior Authorization (PA) Support

Specialty pharmacies submit clinical documentation, appeal denials, and coordinate with prescribers to secure payer approval. First-submission PA denial rates for specialty medications run 25% to 40%, and per-member-per-year specialty costs rose $308 year over year, intensifying payer scrutiny.

The 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule extends the 2024 non-drug PA interoperability requirements to drug PAs, a shift that could reshape how quickly denials are resolved.

The limitation: PA support can appeal a denial, but it cannot change a patient’s clinical need when the denial stems from a formulation or dosing issue the commercial product cannot accommodate.

Financial Assistance Coordination

Specialty pharmacies connect patients to manufacturer copay cards, foundation grants, and patient assistance programs. The roughly 30% affordability-driven discontinuation rate shows this work is necessary but not always sufficient.

The limitation: assistance programs are typically tied to a specific commercial product (NDC). They do not apply if a patient needs a different formulation or strength.

Clinical Case Management

Specialty pharmacists and nurse case managers monitor labs, coordinate with prescribers, and manage side effects in oncology, autoimmune, and rare disease care. This is often the most clinically sophisticated layer of specialty pharmacy, requiring coordination across payers, providers, and patients.

The limitation: case managers coordinate care around the approved product. They have no mechanism to request a modified formulation, which requires a different type of pharmacy entirely.

Cold-Chain and Specialty Packaging/Delivery

Biologics, injectables, and temperature-sensitive drugs require validated cold-chain shipping, specialty packaging, and tight delivery windows. This is a genuine specialty pharmacy strength that compounding pharmacies do not aim to replicate at the same scale, particularly for biologics and cell and gene therapies. Here, compounding plays a narrower, complementary role rather than a direct intersection.

Where the System Breaks: 2026 Pressure Points Patients Are Hitting Right Now

Taken together, these limitations describe a system under strain in 2026.

The PA denial crisis. With 25% to 40% of first-pass specialty PAs denied, and the CMS interoperability rule still in transition, delays and denials remain common even as reform rolls out.

The shortage crisis. ASHP counted 227 active national drug shortages in Q2 2026, the third consecutive quarterly increase. The FDA’s narrower database reported 93 ongoing shortages as of December 31, 2025, and 48% of new 2026 shortages involve sole-source products, meaning there is often no alternate manufacturer.

The GLP-1 case study. The FDA determined that the tirzepatide and semaglutide shortages were resolved. On August 27, 2026, the Fifth Circuit upheld those delisting decisions, closing the 503B bulk-compounding pathway for copies. Only narrow, patient-specific 503A compounding remains, such as for a documented allergy or a medically necessary dose that is not commercially available.

PA denials, shortages, and formulation mismatches are the exact moments when patients and prescribers search for alternatives. They are also where compounding pharmacy legally enters the picture.

Service by Service: Where Compounding Can Legally and Clinically Extend or Unblock Specialty Care

Compounding pharmacies prepare medications from FDA-approved ingredients. They are generally prohibited from copying commercially available drugs unless the FDA has recognized a documented shortage.

The two models also operate under different regulatory frameworks. Specialty pharmacies answer to accreditation bodies (URAC, ACHC, CPPA, The Joint Commission) covering nine operational modules. Compounding pharmacies operate under USP <795>, <797>, and <800>, with PCAB as the voluntary accreditation benchmark and 503A or 503B status determining the level of FDA oversight. The subsections below respond directly to each of the six specialty services.

Dispensing: Filling the Formulation Gap, Not Replacing the Commercial Drug

Compounding cannot recreate a commercially available specialty drug simply for cost or convenience. It steps in only for documented shortages, allergen conflicts, discontinued strengths, or patient-specific clinical needs such as swallowing difficulty or pediatric dosing.

Pediatrics is a clear example. Published research indexed by the National Institutes of Health describes how compounding fills critical gaps in pediatric drug development, where commercial dosage forms often do not exist for a child’s age or weight. Nationwide Compounding Rx® prepares allergen-free formulations without dyes, fillers, or preservatives, and recreates discontinued medication strengths from active ingredients.

Adherence Monitoring: Solving the Root Cause, Not Just Tracking It

When a specialty pharmacy’s monitoring flags non-adherence tied to taste, form, or swallowing, compounding can address the cause directly. Nationwide Compounding Rx® offers capsules, liquids, troches, lozenges, oral and sublingual tablets, suppositories, and pediatric forms like popsicles and suckers. Flavor options include cherry, bubblegum, piña colada, strawberry, and animal-friendly flavors.

This creates a collaborative loop: the specialty pharmacy identifies non-adherence, the prescriber and compounding pharmacy resolve the formulation issue, and the patient returns to therapy.

Prior Authorization Support: An Alternative Pathway When Denials Stall Care

Compounding pharmacies do not perform PA appeals for commercial products. However, when a denial is tied to formulation, dose, or ingredient conflicts rather than pure cost, a clinically appropriate compounded alternative may be available. Within that 25% to 40% denial volume, some cases involve a documented allergy or dosing rationale that could support a 503A compounded prescription instead of a prolonged appeals cycle.

As CMS drug PA reform rolls out, compounding remains a parallel option when speed to therapy matters and the compounded formulation is clinically justified.

Financial Assistance Coordination: A Cash-Pay Bridge, Not a Copay Program Substitute

Compounded medications are not eligible for manufacturer copay cards tied to commercial NDCs. They can, however, offer a transparent and often lower-cost cash-pay option when a clinically appropriate alternative formulation exists. Compounding is not a substitute for foundation grants or insurance navigation. It is a different cost structure, most relevant to the roughly 30% of patients who discontinue specialty therapy over affordability.

Clinical Case Management: A Collaborative Extension, Not a Parallel Track

Nationwide Compounding Rx® uses a provider partnership framework, Connect, Collaborate, Create, Care, that mirrors the collaborative model of specialty case management while focusing on formulation-specific clinical input.

Bioidentical hormone replacement therapy (BHRT) illustrates this well. Formulas can be adjusted at each refill based on updated lab results, requiring ongoing coordination with prescribers. Compounding pharmacists do not manage the overall disease state or insurance. They manage formulation variables such as allergens, dosing, and stability within a care plan directed by the prescriber.

Cold-Chain and Delivery: A Narrower, Complementary Role

This is where compounding’s role is most limited. Compounding pharmacies are not built to replicate biologic cold-chain infrastructure at specialty scale. Overlap exists in timeliness: Nationwide Compounding Rx® offers a 1 to 2 business day turnaround, same-day pickup for some medications, and nationwide shipping tiered by state licensing for sterile and non-sterile preparations. For biologics and cell and gene therapies, specialty pharmacy infrastructure remains unmatched, and compounding does not claim to compete.

The Legal Line: What Compounding Can and Cannot Do Alongside Specialty Pharmacy

Specialty pharmacies dispense FDA-approved, commercially available medications. Compounding pharmacies prepare patient-specific formulations from FDA-approved ingredients, and those formulations are not themselves FDA-approved products. As Cedars-Sinai’s guidance notes, compounding pharmacies generally cannot copy commercially available drugs unless the FDA has documented a shortage.

The GLP-1 timeline shows how this works in practice. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. The Fifth Circuit’s August 27, 2026 ruling upheld the delisting, closing bulk 503B compounding for copies while preserving narrow, documented-need 503A compounding.

What remains legally available is patient-specific compounding for documented allergies, medically necessary doses not commercially manufactured, or discontinued formulations. This is the same standard applied across Nationwide Compounding Rx®’s broader service lines.

Scale confirms that compounding is mainstream. Of roughly 56,000 U.S. community pharmacies, about 7,500 specialize in compounding services, and more than 32,000 offer some form of compounding, dispensing an estimated 30 to 40 million compounded prescriptions annually.

How Nationwide Compounding Rx® Fits Into a Specialty Care Plan

Nationwide Compounding Rx® functions as a partner pharmacy that activates at specific intersection points: PA denials rooted in formulation, allergen conflicts, discontinued strengths, and shortage-driven gaps.

Key credentials for prescribers and patients include:

• PCAB accreditation
• USP <800> compliance
• Independent third-party testing
• Sourcing from FDA-inspected and cleared vendors

The Connect, Collaborate, Create, Care framework serves as the operational bridge between a prescriber’s specialty care plan and a compounded solution. For time-sensitive cases, the pharmacy provides 1 to 2 business day turnaround, same-day pickup for some medications, and nationwide shipping across a tiered licensing structure (fully licensed states, non-sterile only states, and pending states). A dedicated Provider Portal and Patient Portal allow prescriptions and refills to be coordinated without disrupting the existing care plan.

A Practical Decision Framework: When to Loop In a Compounding Pharmacy

The following scenarios may warrant a compounding conversation. In each case, the first step is for the prescriber to document medical necessity and then coordinate with a compounding pharmacy such as Nationwide Compounding Rx® through the provider portal.

1. PA denial tied to formulation or dose, not cost alone. The prescriber documents the clinical rationale for an alternate formulation.
2. Documented allergy to a filler, dye, or preservative. The prescriber records the allergy and requests an allergen-free preparation.
3. Medication on an active FDA-recognized shortage. The prescriber confirms shortage status and discusses an interim compounded option.
4. Discontinued strength or dosage form. The prescriber specifies the needed strength for recreation from active ingredients.
5. Pediatric patient unable to take the commercial form. The prescriber provides age and weight-based dosing for a child-friendly form.
6. BHRT requiring individualized, lab-adjusted ratios. The prescriber shares current labs so the formula can be adjusted at refill.

What does not qualify: simply wanting a cheaper version of a patented biologic or brand-name drug with no documented allergy, shortage, or medically necessary dose difference. That falls outside legal and ethical compounding boundaries.

Conclusion: A Complementary System, Not a Competing One

Specialty pharmacy services in 2026 span six distinct categories, each with real strengths and documented limitations. Compounding legally and clinically extends this system at specific points: formulation-specific dispensing gaps, adherence barriers rooted in dosage form, shortage-driven bridges, and cash-pay alternatives. It never serves as a wholesale substitute for accredited specialty pharmacy infrastructure.

With PA denial rates at 25% to 40%, 227 active shortages, and the GLP-1 compounding pathway narrowed by the Fifth Circuit, patients and prescribers benefit most from knowing exactly when each type of pharmacy is the right tool. Nationwide Compounding Rx® is equipped to step in at those intersection points, in full compliance with PCAB and USP standards.

Talk to Nationwide Compounding Rx® About Your Specialty Care Gap

Prescribers can connect through the Provider Portal to discuss a specific patient scenario, whether a PA denial, allergen conflict, shortage, or discontinued formulation.

Patients and caregivers can reach out through the Patient Portal or website contact form to ask whether their specialty care plan may qualify for a compounded solution.

• Phone: (480) 499-8379
• Hours: Monday to Friday, 7:00 AM to 3:30 PM
• Location: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260
• Email response: within one business day

With PCAB accreditation, USP <800> compliance, and nationwide shipping availability, Nationwide Compounding Rx® helps close the gaps that stand between patients and the therapy they need.